Flomics Biotech, a startup from the Barcelona Biomedical Research Park (PRBB) operating in the genomics and liquid biopsy fields is excited to announce the launch of its seed investment round of 500.000€.
In the last 2 years Flomics’ team has been working in the fine-tuning and validation of its cell-free RNA liquid biopsy technology that will enable early-stage detection of complex diseases from a standard blood sample.
The new investment round will enable Flomics to further capitalize on its position as key player in the liquid biopsy industry and prepare the launch of its first diagnosis product in the field of colon cancer diagnosis. Constant product innovation is a key area of focus for Flomics. The funding will also drive the development of biomarkers for the early detection of other complex diseases such as lung cancer and further international expansion for Flomics genomics services provider arm.
More info: https://www.flomics.com/investors/
About Flomics Biotech
Flomics Biotech is a young biotech company operating in the field of liquid biopsies. Coming from the Barcelona Biomedical Research Park (PRBB) in Spain, Flomics’ mission is to translate the latest research in genomics and cell-free nucleic-acids to clinical practice. Flomics is currently collaborating with hospitals from all around the globe in fighting some of the biggest health challenges that are facing the fields of oncology, infertility and, more recently, epidemiology with coronavirus pandemic.
The research team observed changes in head circumf...
AtCDF3 gene induced greater production of sugars a...
Un estudio con datos de los últimos 35 años, ind...
En nuestro post hablamos sobre este interesante tipo de célula del...
La revista ‘Nature Protocols’ selecciona esta técnica como “pro...
